التفاصيل البيبلوغرافية
| العنوان: |
Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design. |
| المؤلفون: |
Teira Calderón, Andrea1 (AUTHOR), Chiarito, Mauro2,3 (AUTHOR), Santos, Ignacio Amat4,5 (AUTHOR), Cao, Davide3,6 (AUTHOR), Vaquerizo Montilla, Beatriz5,7,8,9 (AUTHOR), Jurado Román, Alfonso10 (AUTHOR), Pulido Garrido, Paloma5 (AUTHOR), Tartaglia, Francesco2,3 (AUTHOR), García-García, Héctor M.11 (AUTHOR), Díez-Gil, Jose Luis1,5 (AUTHOR), Sanz-Sánchez, Jorge1,5 (AUTHOR) sjorge4@gmx.com |
| المصدر: |
Cardiovascular Revascularization Medicine. Jun2024, Vol. 63, p68-72. 5p. |
| مصطلحات موضوعية: |
*TRANSLUMINAL angioplasty, *PERCUTANEOUS coronary intervention, *CORONARY angiography, *ORAL medication, *ATRIAL fibrillation, *ANTICOAGULANTS |
| مستخلص: |
patients with atrial fibrillation (AF) under treatment with chronic oral anticoagulation (OAC) often require coronary angiography with or without percutaneous coronary intervention (PCI). Deciding the management of OAC during this periprocedural period requires balancing the risks of hemorrhage and thrombotic complications. Guidelines recommend an uninterrupted strategy in patients receiving Vitamin-K Antagonists (VKA). However, for patients undergoing coronary angiography or PCI while on direct oral anticoagulants (DOACs), withdrawal 12–24 h prior to the procedure is still recommended. This is based on expert opinions given the lack of evidence. Therefore, whether DOAC discontinuation prior to trans-radial coronary procedures should be the strategy of choice is a matter of debate and solid evidence is needed to guide clinical decision making. The DOAC-NOSTOP study is a prospective, single-arm, open-label study evaluating the safety of DOACs continuation in 200 patients undergoing transradial percutaneous coronary procedures. DOAC treatment will not be interrupted throughout the periprocedural period. Primary outcome will be Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 events, assessed at a 30-day follow-up. The DOAC-NOSTOP is the first study prospectively assessing the risk of bleeding with uninterrupted DOAC in patients undergoing trans-radial percutaneous coronary procedures. Timeline of the DOAC-NOSTOP study. DOAC: Direct-acting oral anticoagulation; BARC: Bleeding Academic Research Consortium. [Display omitted] • Current guidelines suggest DOAC withdrawal pre-procedure based on expert consensus due to limited trial data. • The DOAC-NOSTOP aims to evaluate the safety of uninterrupted DOAC use in these procedures. • The results could impact clinical practice refining recommendations for DOAC management in this context. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
